On September 17-18, 2015, the Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology of the National Academy of Sciences of Ukraine was visited by the Director of the National Cancer Institute (Vilnius, Lithuania), Dr. Eduardas Aleknavičius and the Chairman of the Scientific Council Dr. Ernestas Yanulionis, as well as the Director of the Institute of Physiology of the National Academy of Sciences of Belarus (Minsk, Belarus), Member of the National Academy of Sciences of Belarus, Joseph Zalutsky and the Deputy Director for Science, Corresponding Member of the National Academy of Sciences of Belarus, Vladimir Kulchytsky.
The visitors familiarized themselves with the structure and research areas of the IEPOR, its biotechnology center and translational medicine department and discussed promising areas for future cooperation between the institutions.
As a result of the visit, a tripartite agreement was signed by the Lithuanian National Cancer Institute, Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine, and Institute of Physiology, NAS of Belarus, on the implementation of a joint pilot project entitle «Analysis of the Effectiveness of Therapeutical Anti-Tumour Vaccines in Mouse Experimental Models».
The IEPOR director, Member of the National Academy of Sciences of Ukraine, Vasyl Chekhun noted that the agreement signed by the triumvirate actually paves the road for cancer biotherapy. Today both researchers and clinicians find it difficult to say out loud that so-called «gold standards of cancer treatment» satisfy neither the clinic nor the patient any longer. At the same time, there is a lot of scientific data that make it possible to take a decisive step in the implementation of biotherapies. Of course, it is not a panacea. But this is for sure a step forward. This step opens absolutely new opportunities for new technologies.
The joint Lithuanian-Ukrainian-Belarusian project involves the evaluation and comparison of the effectiveness of auto- and xenogeneic anticancer vaccines in vivo on the models of melanoma and lung carcinoma in mice.